GTC Biotherapeutics (fka GTCB)

[DB9]

GTC Biotherapeutics Inc Is Working With LFB Biotechnologies to Develop Recombinant Forms of Human Factor VIIa and A CD20 Monoclonal Antibody

Last update: 11/6/2008 9:44:01 AM
http://www.tradingmarkets.com/.site/news/Stock%20News/2001105/

DUBLIN, Ireland, Nov 06, 2008 (BUSINESS WIRE) -- Research and Markets () has announced the addition of the "GTC Biotherapeutics Inc: Premium Company Profile" company profile to their offering.

GTC Biotherapeutics is engaged in the development, production and commercialization of therapeutic proteins expressed and purified from the milk of transgenic animals such as goats and cattle. ATryn, the companys major product, is a recombinant human antithrombin produced in the milk of transgenic goats.

Scope of this title - Contains corporate strategy, value chain presence and SWOT Analysis - Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors - Includes information on suppliers/ partners, shareholding structure and key employees with biographies Highlights of this title GTC develops, produces, and commercializes therapeutic proteins through transgenic animal technology.

In addition to ATryn, GTC is working with LFB Biotechnologies to develop recombinant forms of human factor VIIa and a CD20 monoclonal antibody. Total revenues of the company witnessed decline at a CAGR of 11% during 2002-2006, from $10 million to $6 million.

It derives its revenues from collaborative agreements which include non-refundable license fees, funding of research and development, payments based upon the achievement of certain milestones and royalties.

Between 2006 and 2010, the company's revenues are forecasted to increase at a CAGR of 22% from $6 million to $13 million. There will be an absolute growth of +$7 million in the company's total revenues by 2010. The company is expected to receive all of its revenues through collaborative agreements with its partners.